文献速递生殖医学

激动剂长方案改善反复薄型子宫内膜患者冻融胚胎移植结局

Agonist long protocol improves outcomes of vitrified-warmed embryo transfer in repeatedly thin endometrium.
PubMed 文献 · Reprod Biomed Online · 2022-12-07

回顾性研究纳入627例患者共683个冻融胚胎移植周期,既往均至少一次薄型子宫内膜史且口服及阴道雌二醇超过21天后内膜厚度未超过7mm。其中129个周期继续移植,305个周期取消,249个周期采用GnRH激动剂降调节后HMG方案准备内膜。该方案内膜厚度显著大于既往强化雌激素方案(7.18±1.14mm vs 6.13±0.63mm,P<0.001),且临床妊娠率、着床率和活产率均显著提高。

要点

  • 反复薄型子宫内膜患者强化雌激素后内膜未达7mm时,可考虑GnRH激动剂+HMG方案准备内膜。
  • GnRH激动剂+HMG方案内膜厚度7.18±1.14mm,显著大于强化雌激素方案的6.13±0.63mm(P<0.001)。
  • GnRH激动剂+HMG方案后移植的临床妊娠率、着床率和活产率均显著高于强化雌激素方案。

核心结论

  • GnRH激动剂+HMG方案准备内膜可改善强化雌激素后薄型子宫内膜患者的内膜厚度,临床结局显著优于强化雌激素方案。
  • 作者建议对强化雌激素方案无 optimal 反应后内膜厚度小于7mm者使用GnRH激动剂+HMG方案。

研究设计与样本

  • 回顾性研究,纳入627例患者共683个冻融胚胎移植周期,均有至少一次薄型子宫内膜史。
  • 所有周期口服及阴道雌二醇超过21天后内膜厚度未超过7mm(强化雌激素方案)。
  • 129个周期继续移植,305个周期取消,249个周期采用GnRH激动剂降调节后HMG方案准备内膜。

主要发现

  • GnRH激动剂+HMG方案内膜厚度7.18±1.14mm,显著大于既往强化雌激素方案的6.13±0.63mm(P<0.001)。
  • 内膜厚度改善与血清雌激素浓度无关。
  • GnRH激动剂+HMG方案后213个周期进行移植,临床妊娠率、着床率和活产率均显著高于强化雌激素方案后移植。

关键数值与推荐

  • 强化雌激素方案:口服及阴道雌二醇超过21天,内膜厚度未超过7mm。
  • GnRH激动剂+HMG方案:GnRH激动剂降调节后给予HMG准备内膜。
  • 作者建议内膜厚度小于7mm且对强化雌激素方案无 optimal 反应者使用GnRH激动剂+HMG方案。

临床怎么用

  • 对强化雌激素方案后内膜未达7mm的反复薄型子宫内膜患者,作者建议采用GnRH激动剂+HMG方案准备内膜。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does follicular stimulation using human menopausal gonadotrophin (HMG) after pituitary down-regulation by a GnRH agonist improve endometrial thickness (EMT) and clinical outcomes of frozen-thawed embryo transfer (FET; using vitrified-warmed embryos) in women with thin endometrium after intensified oestrogen administration (IOA)? DESIGN: This was a retrospective study. A total of 627 patients attempted 683 FET cycles with at least one previous history of thin endometrium. None of the cycles reached over 7 mm EMT after using oral and vaginal oestradiol for more than 21 days (IOA protocol). A total of 129 cycles proceeded with FET, 305 cycles were cancelled, and 249 cycles involved administration of HMG following GnRH agonist pituitary down-regulation (GnRH agonist + HMG protocol) for further endometrial preparation. RESULTS: EMT became significantly greater (7.18 ± 1.14 mm versus 6.13 ± 0.63 mm, P < 0.001) using GnRH agonist + HMG compared with previous IOA cycles, but this was not related to serum oestrogen concentrations. A total of 213 cycles after the GnRH agonist + HMG protocol proceeded with FET, showing a significantly increased clinical pregnancy rate, implantation rate and live birth rate compared with those after IOA. CONCLUSIONS: The GnRH agonist + HMG protocol for endometrial preparation in FET cycles improves EMT in women with a thin endometrium after IOA and showed significantly better clinical outcomes than IOA. The authors suggest that the GnRH agonist + HMG protocol should be used for EMT that is less than 7 mm after there has been no optimal response to IOA.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Wang P, Yang H, Chen Z, et al. Agonist long protocol improves outcomes of vitrified-warmed embryo transfer in repeatedly thin endometrium. Reprod Biomed Online. 2022. PMID: 36604214. doi:10.1016/j.rbmo.2022.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。